Simplex Trading
GALT icon

Simplex Trading’s Galectin Therapeutics GALT Stock Holding History

Simplex Trading’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.4K Buy
7,300
+1,300
+22% +$3.95K ﹤0.01% 6769
2025
Q4 		$25K Sell
6,000
-45,300
-88% -$239K ﹤0.01% 6271
2025
Q3 		$217K Sell
51,300
-8,600
-14% -$32.4K ﹤0.01% 4844
2025
Q2 		$126K Buy
59,900
+24,500
+69% +$36.7K ﹤0.01% 5000
2025
Q1 		$43K Sell
35,400
-396,800
-92% -$557K ﹤0.01% 5914
2024
Q4 		$557K Buy
432,200
+429,000
+13,406% +$1.03M ﹤0.01% 3409
2024
Q3 		$8K Buy
3,200
+2,600
+433% +$6.38K ﹤0.01% 7319
2024
Q2 		$1K Sell
600
-6,400
-91% -$19.4K ﹤0.01% 8467
2024
Q1 		$16K Sell
7,000
-2,300
-25% -$4.35K ﹤0.01% 7262
2023
Q4 		$15K Sell
9,300
-600
-6% -$1.16K ﹤0.01% 7133
2023
Q3 		$19K Hold
9,900
– – ﹤0.01% 6660
2023
Q2 		$14K Sell
9,900
-800
-7% -$1.36K ﹤0.01% 7093
2023
Q1 		$22K Sell
10,700
-39,300
-79% -$63.5K ﹤0.01% 6814
2022
Q4 		$56K Buy
50,000
+17,600
+54% +$23.4K ﹤0.01% 5727
2022
Q3 		$52K Sell
32,400
-16,300
-33% -$30.5K ﹤0.01% 6400
2022
Q2 		$63K Buy
48,700
+31,800
+188% +$45.7K ﹤0.01% 6184
2022
Q1 		$27K Buy
16,900
+11,000
+186% +$21.3K ﹤0.01% 7891
2021
Q4 		$12K Sell
5,900
-17,200
-74% -$49.1K ﹤0.01% 8860
2021
Q3 		$75K Hold
23,100
– – ﹤0.01% 7013
2021
Q2 		$73K Buy
23,100
+22,915
+12,386% +$81.5K ﹤0.01% 7167
2021
Q1 		$40K Sell
185
-92
-33% -$206 ﹤0.01% 6855
2020
Q4 		$62K Buy
277
+87
+46% +$228 ﹤0.01% 5947
2020
Q3 		$50K Buy
190
+77
+68% +$216 ﹤0.01% 5600
2020
Q2 		$34K Sell
113
-5
-4% -$13 ﹤0.01% 5819
2020
Q1 		$23K Sell
118
-16
-12% -$39 ﹤0.01% 5830
2019
Q4 		$38K Buy
134
+33
+33% +$115 ﹤0.01% 5447
2019
Q3 		$37K Sell
101
-31
-23% -$112 ﹤0.01% 5303
2019
Q2 		$54K Buy
132
+62
+89% +$268 ﹤0.01% 4784
2019
Q1 		$35K Sell
70
-160
-70% -$768 ﹤0.01% 5284
2018
Q4 		$78K Sell
230
-19
-8% -$91 ﹤0.01% 4089
2018
Q3 		$149K Buy
249
+123
+98% +$677 ﹤0.01% 3982
2018
Q2 		$80K Buy
126
+12
+11% +$58 ﹤0.01% 4529
2018
Q1 		$6K Buy
+114
New +$531 ﹤0.01% 4472
2017
Q4 		– Sell
-81
Closed -$6K – 6203
2017
Q3 		$6K Sell
81
-13
-14% -$26 ﹤0.01% 4227
2017
Q2 		$8K Buy
94
+71
+309% +$189 ﹤0.01% 4160
2017
Q1 		$3K Buy
+23
New +$35 ﹤0.01% 4978
2016
Q4 		– Sell
-53
Closed -$7K – 6054
2016
Q3 		$7K Buy
53
+40
+308% +$71 ﹤0.01% 3936
2016
Q2 		$7K Sell
13
-12
-48% -$18 ﹤0.01% 3920
2016
Q1 		$15K Buy
+25
New +$34 ﹤0.01% 3057
2015
Q1 		– Sell
-97
Closed -$89K – 5147
2014
Q4 		$89K Buy
+97
New +$429 0.01% 994

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Simplex Trading's GALT Position: Q1 2026 in Review

Simplex Trading increased its Galectin Therapeutics (GALT) stake by 1,406% in Q1 2026, buying an estimated $239K and bringing the position to 84,000 shares worth $234K. The position accounts for ﹤0.01% of the portfolio, ranked #4115.

Simplex Trading first reported a position in GALT in Q4 2014 and has held it in 33 quarters since. The position peaked at $285K in Q3 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • Simplex Trading held 84,000 shares of Galectin Therapeutics worth $234K as of Q1 2026.
  • Simplex Trading bought 78,421 Galectin Therapeutics shares in Q1 2026, an estimated $239K.
  • Galectin Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #4115 holding.
  • Simplex Trading first reported a position in Galectin Therapeutics in Q4 2014 and has held it in 33 quarters since.
  • Simplex Trading's Galectin Therapeutics position peaked at $285K in Q3 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.